Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Makoto Otsu is active.

Publication


Featured researches published by Makoto Otsu.


Leukemia | 2014

Haploinsufficiency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia.

M Matsunawa; Ryo Yamamoto; Masashi Sanada; Aiko Sato-Otsubo; Yusuke Shiozawa; Kenichi Yoshida; Makoto Otsu; Yuichi Shiraishi; Satoru Miyano; Kyoichi Isono; Haruhiko Koseki; Hiromitsu Nakauchi; Seishi Ogawa

SF3B1 is a core component of the mRNA splicing machinery and frequently mutated in myeloid neoplasms with myelodysplasia, particularly in those characterized by the presence of increased ring sideroblasts. Deregulated RNA splicing is implicated in the pathogenesis of SF3B1-mutated neoplasms, but the exact mechanism by which the SF3B1 mutation is associated with myelodysplasia and the increased ring sideroblasts formation is still unknown. We investigated the functional role of SF3B1 in normal hematopoiesis utilizing Sf3b1 heterozygous-deficient mice. Sf3b1+/− mice had a significantly reduced number of hematopoietic stem cells (CD34−cKit+ScaI+Lin− cells or CD34−KSL cells) compared with Sf3b1+/+ mice, but hematopoiesis was grossly normal in Sf3b1+/− mice. When transplanted competitively with Sf3b1+/+ bone marrow cells, Sf3b1+/− stem cells showed compromised reconstitution capacity in lethally irradiated mice. There was no increase in the number of ring sideroblasts or evidence of myeloid dysplasia in Sf3b1+/− mice. These data suggest that SF3B1 plays an important role in the regulation of hematopoietic stem cells, whereas SF3B1 haploinsufficiency itself is not associated with the myelodysplastic syndrome phenotype with ring sideroblasts.


Molecular Therapy | 2004

272. Development of |[ldquo]|Full|[rdquo]|-Closed Sterile and Automatic Retroviral Gene Transfer System for Clinical Gene Therapy

Shin Kaneko; Makoto Otsu; Yuichi Hasegawa; Hiroshi Kojima; Takashi Shimizu; Takashi Fukushima; Ryo Sumazaki; Masafumi Onodera; Toshiro Nagasawa

Manipulating large number of cultured cells for gene therapy has risk of microbiological contamination constantly. It would become more serious under the situation like re-infusion of such cells to the compromised host. Our clinical protocol, HSV-TK gene transfer into donor lymphocytes for control of allogeneic Graft-versus-leukemia and Graft-versus-host-disease (Japanese trial), is one of such sensitive protocol by meaning of immunological conditions of patients and manipulation steps. To avoid those problems we are developing manipulation protocol for retroviral gene transfer to human T lymphocytes using automatic cell processor CytoMateTM, magnetic cell selection system IsolexTM and CO2 permeable cell culture bag OpticytoTM. All of manipulations, except centrifugation for gene transfer, had been performed in full-closed sterile conditions. Function and sterility of final products, HSV-TK gene transferred lymphocytes, were evaluated by comparing with non-closed system, using centrifugation tubes and flasks.


Molecular Therapy | 2004

330. Genetic Modification of Murine Embryonic Stem Cells by the Gene Silencing Resistance Retroviral Vector GCDsap

Sanae Hamanaka; Joichi Usui; Satoru Takahashi; Hisahiro Yoshida; Michio Nagata; Makoto Otsu; Shin Kaneko; Toshiro Nagasawa; Hiromitsu Nakauchi; Masafumi Onodera

In the last ASGT meeting, we presented that the retroviral vector GCDsap with high resistance to gene silencing maintained expression of the transgene (EGFP) in mouse embryonic stem (ES) cells over 60 days and the expression was continued even after differentiation of the transduced ES cells into three germ layers of teratomas in NOD/SCID mice. In this study, to assess the ability of the vector to maintain the transgene expression through ontogeny, the transduced ES cells were injected into C57BL/6 mouse 3.5 days blastocytes and chimeric mice were generated. The birth ratio of chimeric mice determined by coat color was 67% (24 out of 36 mice) and 17 out of 24 mice (71%) highly expressed EGFP in their tissues, including hematopoietic cells, neurons, muscles, and intestinal tracts. Furthermore, such high expression of EGFP was transmitted through F1 (47/95 = 49%) to F2 mice (32/56 = 58%) generated by mating with C57BL/6 mice. Although the mean intensity of EGFP varied among the mice, some had 100% of EGFP expressing cells in their peripheral blood. Interestingly, a chimera mouse gave rise to F1 mice that were divided into three groups by the expression patterns in their peripheral blood. Southern blot analyses revealed that the chimeric mouse had 8 copies of proviruses integrated in its chromosomes and each F1 group showed an identical integration pattern of proviruses. This was applicable to F2 mice, in particular, F2 mice borne by F1 mice with the highest EGFP expression also showed high EGFP expression and their integration patterns were identical to that of the F1, suggesting that maintenance of the transgene expression was greatly influenced by the integration sites as well as vector structures. Taken together, it is likely that GCDsap provided a useful tool not only for future regenerative medicine, but also for analysis of epigenetic changes in chromosomes during gonogenesis.


Molecular Therapy | 2006

Potent Vaccine Therapy with Dendritic Cells Genetically Modified by the Gene-Silencing-Resistant Retroviral Vector GCDNsap

Tsukasa Nabekura; Makoto Otsu; Toshiro Nagasawa; Hiromitsu Nakauchi; Masafumi Onodera


Archive | 2008

METHOD FOR ESTABLISHING iPS CELL

Dong Hyuk Ahn; Hiromitsu Nakauchi; Makoto Otsu; 啓光 中内; 真 大津; 東赫 安


Open Journal of Hematology | 2015

Reactive oxygen species in hematopoietic stem cells affect culture outcomes under inflammatory conditions

Takashi Ishida; Satoshi Yamazaki; Hiromitsu Nakauchi; Masaaki Higashihara; Makoto Otsu


Molecular Therapy | 2006

1088. Stem Cell Gene Therapy with No Pre-Conditioning for the ADA-Deficiency Patients Leads to Generalized Detoxification and Delayed, but Steady Hematological Reconstitution

Makoto Otsu; Satoru Nakajima; Miyuki Kida; Yoshihiro Maeyama; Nariaki Toita; Norikazu Hatano; Nobuaki Kawamura; Ryouji Kobayashi; Osamu Tatsuzawa; Masafumi Onodera; Fabio Candotti; Pawan Bali; Michael S. Hershfield; Yukio Sakiyama; Tadashi Ariga


Molecular Therapy | 2006

1107. Gene Therapy Clinical Trials for Relapsed Leukemia with Infusions of the Suicide-Gene Transduced Donor Lymphocytes in Japan

Masafumi Onodera; Shin Kaneko; Makoto Otsu; Hiroshi Kojima; Ryo Sumazaki; Salvatore Toma; Chiara Bonini; Claudio Bordignon; Hiromitsu Nakauchi; Toshiro Nagasawa


Molecular Therapy | 2005

35. Generalized Detoxification Associated with Engraftment of Gene-Corrected Repopulating Cells Achieved in ADA-SCID Patients by Stem Cell Gene Therapy without Myelopreparative Pre-Conditioning

Makoto Otsu; Satoru Nakajima; Miyuki Kida; Yoshihiro Maeyama; Nariaki Toita; Norikazu Hatano; Nobuaki Kawamura; Motohiko Okano; Ryouji Kobayashi; Osamu Tatsuzawa; Masafumi Onodera; Fabio Candotti; Michael S. Hershfield; Yukio Sakiyama; Tadashi Ariga


Archive | 2016

Brief report Definitive proof for direct reprogramming of hematopoietic cells to pluripotency

Motohito Okabe; Makoto Otsu; Dong Hyuck Ahn; Toshihiro Kobayashi; Yohei Morita; Yukiko Wakiyama; Masafumi Onodera; Koji Eto; Hideo Ema; Hiromitsu Nakauchi

Collaboration


Dive into the Makoto Otsu's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fabio Candotti

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge